SENZIME AB INVITES TO AN WEBCAST TODAY, JUNE 2 AT 11.00 A.M. CEST
Senzime AB (publ), announced on June 1 that the company has entered into an agreement to acquire the US company Respiratory Motion. Following this announcement, Senzime invites investors, analysts, and media to an webcast (in English) with a Q&A-session on June 2, at 11:00 a.m. CEST.
The presentation will be held by Senzime's CEO Pia Renaudin, Philip Siberg, Chairman of the Board, Jonathan Ekman, Head of M&A and Professor Lars I Eriksson from the section for Anesthesiology and Intensive Care at the Department of Physiology and Pharmacology at Karolinska University Hospital. The webcast will conclude with a Q&A session. No preregistration is required.
The webcast will also be available on demand on Senzime’s corporate website after the event.
Senzime is a Swedish medical device company that develops and markets CE- and FDA-cleared monitoring systems for patients undergoing anesthesia. Senzime’s employees worldwide are committed to the vision of a world without anesthesia related complications. Six out of ten patients that wake up after surgery are not fully muscle recovered and therefor at risk having critical respiratory complications. The TetraGraph system helps anesthesia providers improve patient care and reduce healthcare costs by digitally and continuously measure the degree of neuromuscular blockade under and after surgery. Senzime operates in the worlds leading markets targeting a market opportunity valued in excess of SEK 15 billion per year. The company’s shares are listed on Nasdaq Stockholms main market (ticker SEZI). www.senzime.com